An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.

IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan
{"title":"An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.","authors":"Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan","doi":"10.1007/s11845-025-04113-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.</p><p><strong>Methods: </strong>An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.</p><p><strong>Results: </strong>In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).</p><p><strong>Conclusion: </strong>In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.</p>","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-04113-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.

Methods: An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.

Results: In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).

Conclusion: In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.

在癌症诊断的情况下,爱尔兰皮肤科顾问治疗严重牛皮癣的处方偏好评估。
目的:我们旨在调查爱尔兰皮肤科医生对牛皮癣和癌症诊断患者的系统和生物药物选择。方法:在2023年12月至2025年6月期间,通过Jotform调查平台向爱尔兰皮肤病协会成员分发电子问卷。结果:共27例。甲氨蝶呤最常用于缓解期至5年的所有情况。在所有的临床情况下,富马酸酯是最不常选择的药物。一般来说,肿瘤坏死因子- α抑制剂是次最少被选择的药物。阿普雷米司特最常用于1期乳腺癌(26%)、淋巴瘤(22%)和转移性RCC(30%)的当前恶性肿瘤。结论:总的来说,爱尔兰皮肤科医生在牛皮癣和癌症的治疗中使用了系统和生物制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Irish Journal of Medical Science
Irish Journal of Medical Science 医学-医学:内科
CiteScore
3.70
自引率
4.80%
发文量
357
审稿时长
4-8 weeks
期刊介绍: The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker. The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信